REHOVOT, Israel, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (PPBT) ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that ...
-Highlights potential uses of Celularity (CELU) biomaterials in regenerative medicine applications that combine stem cells and biomaterial scaffolds for use in constructing tissues and for cell ...
- CRG-023 is a CD19-, CD20-, CD22-targeting tri-specific CAR T product candidate designed with the goal of providing more patients with a broad range of B-cell malignancies with durable responses by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results